Advertisement
ALNY or INCY or IONS
Which Stock Would AI Choose? Alnylam Pharmaceuticals (ALNY) vs. Incyte Corporation (INCY) vs. Ionis Pharmaceuticals (IONS) Stock Comparison
Key Takeaways
- ALNY leads with robust revenue growth from its RNAi platform, projecting $4.9-$5.3 billion in 2026 net product revenues, driven by TTR franchise expansion.
- INCY offers commercial stability in oncology and inflammation, with $5.14 billion in 2025 revenues but conservative 2026 guidance raising near-term concerns.
- IONS advances antisense tech with multiple 2026 catalysts, including launches for olezarsen and zilganersen, amid pipeline momentum in neurology and metabolic diseases.
- All three exhibit strong 1-year returns around 17-49%, though YTD performances vary: INCY positive at 8.55%, while ALNY and IONS face recent pressure.
- ALNY's $42 billion market cap dwarfs peers, reflecting premium valuation (P/E ~136), versus INCY's value-oriented profile.
- Biotech sector headwinds impact sentiment, but pipeline catalysts position each for relative outperformance in RNA-focused innovation.
Introduction
This comparison examines ALNY, INCY, and IONS, leaders in RNA therapeutics and oncology. ALNY pioneers RNAi for rare diseases, INCY focuses on small-molecule drugs in hematology and dermatology, and IONS advances antisense oligonucleotides (ASOs, synthetic DNA-like molecules that target RNA) across neurology and metabolic disorders. Investors tracking biotech stock comparison and relative performance will value insights into their market positioning amid recent earnings, pipeline updates, and sector volatility. Traders may eye momentum shifts, while long-term holders assess growth sustainability in innovative therapies.
ALNY Overview and Recent Performance
Alnylam Pharmaceuticals (ALNY) specializes in RNA interference (RNAi, a natural process where RNA molecules inhibit gene expression) therapeutics for rare genetic diseases, particularly transthyretin-mediated amyloidosis (ATTR). In recent market activity, the stock trades around $316 with a $42 billion market cap, reflecting YTD declines amid biotech pressures but 18% 1-year gains. Q4 2025 revenues hit $995 million (up 121% YoY), driving full-year $3 billion (81% growth), fueled by AMVUTTRA approvals in ATTR-CM (cardiomyopathy). The "Alnylam 2030" strategy and 2026 guidance of $4.9-$5.3 billion bolster sentiment, though competition tempers near-term momentum. Beta of 0.38 signals lower volatility, with P/E ~136 indicating growth premium.
INCY Overview and Recent Performance
Incyte Corporation (INCY) develops small-molecule therapies for oncology, hematology, and inflammation, anchored by Jakafi (ruxolitinib, a JAK inhibitor for myelofibrosis). Trading near $90 with a ~$20 billion market cap, the stock shows YTD gains of 8.55% and 49% over 1 year. Q4 2025 revenues reached $1.51 billion (28% YoY growth), full-year $5.14 billion (21% up), but EPS miss and 2026 guidance ($4.77-$4.94 billion) pressured shares. Positive data for povorcitinib in hidradenitis suppurativa (HS, chronic skin condition) and approvals like Zynyz expand the pipeline. Jakafi XR launch potential offsets 2028 patent expiry risks, supporting steady performance.
IONS Overview and Recent Performance
Ionis Pharmaceuticals (IONS) leverages antisense technology for neurological, rare, and cardiovascular diseases. At ~$72 with a smaller market cap, it posted 127% 1-year returns but YTD softness. Q4 2025 results beat estimates, with full-year revenues up 34% to $944 million, driven by TRYNGOLZA launch ($108 million). 2026 catalysts include olezarsen sNDA Priority Review (PDUFA June) for severe hypertriglyceridemia (sHTG, high blood triglycerides) and zilganersen NDA for Alexander disease (AxD, rare leukodystrophy). Peak sales potential over $2 billion for TRYNGOLZA and cash flow breakeven by 2028 fuel optimism, despite operating loss guidance.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the platform's top performers from hundreds of AI trading bots that analyze thousands of tickers across diverse strategies. With over 351 bots total—spanning AI Trading Signal Agents for real-time alerts, Virtual Agents with customizable risk controls, and Brokerage Agents for automated copy trading—the trending section spotlights 25 elite models suited to current market conditions like biotech volatility and sector rotations. These bots employ varied styles, from pattern recognition on short timeframes to momentum strategies over weeks, posting impressive stats like 30-day annualized returns up to 171% and win rates exceeding 88% in top cases. AI dynamically ranks them for optimal conditions, helping traders navigate stocks like ALNY, INCY, and IONS. Explore Trending AI Robots to deploy data-driven strategies today.
Head-to-Head Comparison
ALNY, INCY, and IONS contrast in business models: ALNY's RNAi targets rare diseases with high-growth TTR focus; INCY's small molecules emphasize diversified oncology/inflammation revenue; IONS' ASOs span neurology/metabolics via partnerships. Growth drivers highlight ALNY's 64-77% projected 2026 surge versus INCY's steadier 9% and IONS' launch ramps. Recent momentum favors INCY's YTD edge, but IONS boasts superior 1-year gains. Risks include ALNY/ IONS' pipeline dependency versus INCY's Jakafi cliff; all share biotech sector exposure. Valuation sensitivity prices ALNY at growth premium (P/E 136, beta 0.38), INCY as value play, IONS on catalysts. Market sentiment tilts to ALNY's scale amid RNA innovation trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors ALNY for its trend consistency in RNAi leadership, profitability inflection, and superior 2026 revenue trajectory amid stable catalysts like AMVUTTRA uptake. While INCY offers relative stability and IONS pipeline upside, ALNY's positioning suggests higher probabilistic outperformance in the biotech rally.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALNY’s FA Score shows that 1 FA rating(s) are green whileINCY’s FA Score has 1 green FA rating(s), and IONS’s FA Score reflects 0 green FA rating(s).
- ALNY’s FA Score: 1 green, 4 red.
- INCY’s FA Score: 1 green, 4 red.
- IONS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALNY’s TA Score shows that 2 TA indicator(s) are bullish while INCY’s TA Score has 5 bullish TA indicator(s), and IONS’s TA Score reflects 4 bullish TA indicator(s).
- ALNY’s TA Score: 2 bullish, 7 bearish.
- INCY’s TA Score: 5 bullish, 4 bearish.
- IONS’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALNY (@Biotechnology) experienced а -3.87% price change this week, while INCY (@Biotechnology) price change was +1.82% , and IONS (@Biotechnology) price fluctuated +0.72% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.61%. For the same industry, the average monthly price growth was +9.02%, and the average quarterly price growth was +11.47%.
Reported Earning Dates
ALNY is expected to report earnings on Apr 30, 2026.
INCY is expected to report earnings on Apr 28, 2026.
IONS is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Biotechnology (+7.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ALNY | INCY | IONS | |
| Capitalization | 41.3B | 19.5B | 12.5B |
| EBITDA | 631M | 1.76B | -273.12M |
| Gain YTD | -22.127 | -0.962 | -4.298 |
| P/E Ratio | 132.90 | 15.26 | N/A |
| Revenue | 3.71B | 5.14B | 944M |
| Total Cash | 2.91B | 3.58B | 2.68B |
| Total Debt | 1.28B | 40.4M | 2.07B |
ALNY | INCY | IONS | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 69 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 69 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 53 | 72 | 62 | |
SMR RATING 1..100 | 15 | 32 | 98 | |
PRICE GROWTH RATING 1..100 | 60 | 49 | 41 | |
P/E GROWTH RATING 1..100 | 100 | 100 | 74 | |
SEASONALITY SCORE 1..100 | 50 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INCY's Valuation (69) in the Biotechnology industry is in the same range as ALNY (94) and is in the same range as IONS (100). This means that INCY's stock grew similarly to ALNY’s and similarly to IONS’s over the last 12 months.
ALNY's Profit vs Risk Rating (53) in the Biotechnology industry is in the same range as IONS (62) and is in the same range as INCY (72). This means that ALNY's stock grew similarly to IONS’s and similarly to INCY’s over the last 12 months.
ALNY's SMR Rating (15) in the Biotechnology industry is in the same range as INCY (32) and is significantly better than the same rating for IONS (98). This means that ALNY's stock grew similarly to INCY’s and significantly faster than IONS’s over the last 12 months.
IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as INCY (49) and is in the same range as ALNY (60). This means that IONS's stock grew similarly to INCY’s and similarly to ALNY’s over the last 12 months.
IONS's P/E Growth Rating (74) in the Biotechnology industry is in the same range as INCY (100) and is in the same range as ALNY (100). This means that IONS's stock grew similarly to INCY’s and similarly to ALNY’s over the last 12 months.
| ALNY | INCY | IONS | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 63% | 2 days ago 80% |
| Stochastic ODDS (%) | 2 days ago 63% | 2 days ago 57% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 63% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 67% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 63% | 2 days ago 71% |
| TrendMonth ODDS (%) | 2 days ago 69% | 2 days ago 60% | 2 days ago 74% |
| Advances ODDS (%) | 5 days ago 76% | 10 days ago 61% | 4 days ago 66% |
| Declines ODDS (%) | 2 days ago 66% | 3 days ago 60% | 6 days ago 65% |
| BollingerBands ODDS (%) | 2 days ago 87% | 2 days ago 67% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 71% | 2 days ago 60% | 2 days ago 74% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| NACP | 53.32 | 0.58 | +1.11% |
| Impact Shares NAACP Minority Empwrmt ETF | |||
| JIVE | 91.33 | 0.86 | +0.95% |
| JPMorgan International Value ETF | |||
| TBFC | 29.06 | 0.17 | +0.60% |
| The Brinsmere Fund - Conservative ETF | |||
| XUDV | 29.51 | 0.05 | +0.18% |
| Franklin U.S. Dividend Mltplr Idx ETF | |||
| BRKU | 21.24 | -0.10 | -0.45% |
| Direxion Daily BRKB Bull 2X Shares | |||